This paper presents a summary of the evidence review group (ERG) report into the clinical
effectiveness and cost-effectiveness of azacitidine (aza) compared with conventional care
regimes (CCR) for higher risk patients with myelodysplastic syndrome (MDS), chronic
myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), based on the
evidence submission from the manufacturer to the National Institute for Health and Clinical
Excellence (NICE) as part of the single technology appraisal process. The patient outcomes …